Nanoparticle-mediated angiotensin-(1-9) drug delivery for the treatment of cardiac hypertrophy

Vista sencilla de ítem
dc.contributor.authorSepúlveda-Rivas, Sabrina
dc.contributor.authorLeal, Matías S.
dc.contributor.authorPedrozo, Zully
dc.contributor.authorKogan, Marcelo J.
dc.contributor.authorOcaranza, María Paz
dc.contributor.authorMorales, Javier O.
dc.date.accessioned2023-10-03T20:59:22Z
dc.date.available2023-10-03T20:59:22Z
dc.date.issued2021-06
dc.descriptionIndexación: Scopuses
dc.description.abstractAng-(1-9) peptide is a bioactive vasodilator peptide that prevents cardiomyocyte hypertrophy in vitro and in vivo as well as lowers blood pressure and pathological cardiovascular remodeling; however, it has a reduced half-life in circulation, requiring a suitable carrier for its delivery. In this work, hybrid nanoparticles composed of polymeric nanoparticles (pNPs) based on Eudragit® E/Alginate (EE/Alg), and gold nanospheres (AuNS), were developed to evaluate their encapsulation capacity and release of Ang-(1-9) under different experimental conditions. Hybrid pNPs were characterized by dynamic light scattering, zeta potential, transmission and scanning electron microscopy, size distribution, and concentration by nanoparticle tracking analysis. Nanometric pNPs, with good polydispersity index and colloidally stable, produced high association efficiency of Ang-(1-9) and controlled release. Finally, the treatment of neonatal cardiomyocytes in culture with EE/Alg/AuNS 2% + Ang-(1-9) 20% pNPs decreased the area and perimeter, demonstrating efficacy in preventing norepinephrine-induced cardiomyocyte hypertrophy. On the other hand, the incorporation of AuNS did not cause negative effects either on the cytotoxicity or on the association capacity of Ang-(1-9), suggesting that the hybrid carrier EE/Alg/AuNS pNPs could be used for the delivery of Ang-(1-9) in the treatment of cardiovascular hypertrophy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.es
dc.description.urihttps://www.mdpi.com/1999-4923/13/6/822
dc.identifier.citationPharmaceutics Volume 13, Issue 62021June Article number 822es
dc.identifier.doi10.3390/pharmaceutics13060822
dc.identifier.issn1999-4923
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/53405
dc.language.isoenes
dc.publisherMDPIes
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectAngiotensin-(1-9)es
dc.subjectCardiac hypertrophyes
dc.subjectGold nanoparticleses
dc.subjectPeptide deliveryes
dc.subjectPolymeric nanoparticleses
dc.titleNanoparticle-mediated angiotensin-(1-9) drug delivery for the treatment of cardiac hypertrophyes
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Sepulveda_S_Nanoparticle_Mediated_Angiotensin_2021_Article.pdf
Tamaño:
4.32 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista